Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Valneva; UBM (03/12/2024)

08.12.2024

Valneva: Valneva SE, a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated. Among the 278 healthy adults still enrolled in the trial, 96% maintained neutralizing antibody titers well above the seroresponse threshold three years after the single-dose vaccination. Persistence of antibodies in older adults (age 65+) in terms of geometric mean titers (GMTs) and seroresponse rates (SRRs) was comparable to younger adults (18-64 years of age). Hence, the primary endpoint was met.
Valneva: weekly performance: 4.61%

UBM: UBM Development is selling a non-core asset in Poland for €17.85m to a polish entity – Rewa prosta spółka akcyjna (simple joint stock company) with its registered office in Cracow. The project Galeria Szperk is a shopping center with 57 well-known chains, national and local brands, including attractive retail and service outlets in Kosakowo (Gdynia), Poland. Thomas G. Winkler, CEO of UBM Development AG, explains: “Liquidity over profitability is UBM’s mantra in 2024 and our transaction in Gdynia lives up to this approach.”
UBM: weekly performance: -6.47%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (03/12/2024)


Partners









latest 21st Austria

21st Austria weekly - Valneva; UBM (03/12/2024)


08.12.2024, 1436 Zeichen



Valneva: Valneva SE, a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated. Among the 278 healthy adults still enrolled in the trial, 96% maintained neutralizing antibody titers well above the seroresponse threshold three years after the single-dose vaccination. Persistence of antibodies in older adults (age 65+) in terms of geometric mean titers (GMTs) and seroresponse rates (SRRs) was comparable to younger adults (18-64 years of age). Hence, the primary endpoint was met.
Valneva: weekly performance: 4.61%

UBM: UBM Development is selling a non-core asset in Poland for €17.85m to a polish entity – Rewa prosta spółka akcyjna (simple joint stock company) with its registered office in Cracow. The project Galeria Szperk is a shopping center with 57 well-known chains, national and local brands, including attractive retail and service outlets in Kosakowo (Gdynia), Poland. Thomas G. Winkler, CEO of UBM Development AG, explains: “Liquidity over profitability is UBM’s mantra in 2024 and our transaction in Gdynia lives up to this approach.”
UBM: weekly performance: -6.47%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (03/12/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice 25/365: Dominik Hojas heute als Voice für Bildung in mehrerlei Hinsicht




 

Bildnachweis

Aktien auf dem Radar:EuroTeleSites AG, Rosenbauer, Porr, Austriacard Holdings AG, AT&S, Lenzing, Uniqa, Pierer Mobility, FACC, DO&CO, Zumtobel, Josef Manner & Comp. AG, Warimpex, UBM, RHI Magnesita, SW Umwelttechnik, Flughafen Wien, Oberbank AG Stamm, Addiko Bank, Agrana, Amag, EVN, OMV, Österreichische Post, Telekom Austria, VIG, Wienerberger, MTU Aero Engines, HeidelbergCement, SAP, Siemens Energy.


Random Partner

Evotec
Evotec ist ein Wirkstoffforschungs- und -entwicklungsunternehmen, das in Forschungsallianzen und Entwicklungspartnerschaften mit Pharma- und Biotechnologieunternehmen, akademischen Einrichtungen, Patientenorganisationen und Risikokapitalgesellschaften Ansätze zur Entwicklung neuer pharmazeutischer Produkte vorantreibt.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten